AR100367A1 - Anticuerpos biespecíficos químicamente bloqueados - Google Patents
Anticuerpos biespecíficos químicamente bloqueadosInfo
- Publication number
- AR100367A1 AR100367A1 ARP150101429A ARP150101429A AR100367A1 AR 100367 A1 AR100367 A1 AR 100367A1 AR P150101429 A ARP150101429 A AR P150101429A AR P150101429 A ARP150101429 A AR P150101429A AR 100367 A1 AR100367 A1 AR 100367A1
- Authority
- AR
- Argentina
- Prior art keywords
- chemically blocked
- antibodies
- biespectific
- bispecific
- igg class
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describe un proceso para formar anticuerpos biespecíficos o heterodiméricos químicamente bloqueados, preferentemente en la clase IgG, en elevada especificidad y con elevada homogeneidad. Más específicamente, se describe un anticuerpo de clase IgG biespecífico químicamente bloqueado que tiene una región de ligación unida con química clic bio-ortogonal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461991508P | 2014-05-10 | 2014-05-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR100367A1 true AR100367A1 (es) | 2016-09-28 |
Family
ID=54480478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150101429A AR100367A1 (es) | 2014-05-10 | 2015-05-11 | Anticuerpos biespecíficos químicamente bloqueados |
Country Status (9)
Country | Link |
---|---|
US (1) | US10435479B2 (es) |
EP (1) | EP3143154B1 (es) |
JP (1) | JP6687247B2 (es) |
KR (1) | KR102460736B1 (es) |
CN (1) | CN106661602B (es) |
AR (1) | AR100367A1 (es) |
AU (1) | AU2015259533B2 (es) |
CA (1) | CA2948810A1 (es) |
WO (1) | WO2015175357A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4137158A1 (en) | 2015-08-07 | 2023-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
CN108473574A (zh) * | 2015-10-20 | 2018-08-31 | 索伦托治疗有限公司 | 细胞内递送化合物 |
EP3377112A4 (en) * | 2015-11-18 | 2019-06-12 | Sorrento Therapeutics, Inc. | CHEMICALLY BLOCKED BISPECIFIC ANTIBODIES |
WO2017218891A1 (en) * | 2016-06-17 | 2017-12-21 | Life Technologies Corporation | Site-specific crosslinking of antibodies |
CA3035254A1 (en) * | 2016-09-01 | 2018-03-08 | Immunomab, Inc. | Bispecific antibodies |
CA3143066A1 (en) * | 2016-10-17 | 2018-04-26 | Shenzhen Enduring Biotech, Ltd. | Long acting multi-specific molecules and related methods |
US20180194859A1 (en) * | 2017-01-12 | 2018-07-12 | Sorrento Therapeutics, Inc. | Linked Dual Antibodies Conjugated at a Hinge Region |
WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
US11701440B2 (en) | 2018-04-16 | 2023-07-18 | Nihon Medi-Physics Co., Ltd. | Modified antibody and radioactive metal-labelled antibody |
US20240182950A1 (en) * | 2022-10-21 | 2024-06-06 | Quantum-Si Incorporated | Methods and systems for characterizing phosphoserine-containing polypeptides |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185433A (en) * | 1990-04-09 | 1993-02-09 | Centocor, Inc. | Cross-linking protein compositions having two or more identical binding sites |
AU2004308439A1 (en) | 2003-12-22 | 2005-07-14 | Centocor, Inc. | Methods for generating multimeric molecules |
ES2667863T3 (es) * | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
EP2400992B1 (en) * | 2009-02-27 | 2015-07-22 | Genentech, Inc. | Methods and compositions for protein labelling |
BR112012012983A2 (pt) | 2009-12-04 | 2020-09-15 | Genentech Inc | método para sintetizar um anticorpo multiespecífico, método para sintetizar um painel de anticorpos multiespecíficos, método para sintetizar um análogo de anticorpo, método para sintetizar um painel de análogos de anticorpo e composições |
ME02505B (me) * | 2009-12-29 | 2017-02-20 | Aptevo Res & Development Llc | Heterodimerni vezujući proteini i njihove upotrebe |
CN103261222B (zh) | 2010-09-10 | 2017-07-28 | 医疗免疫有限公司 | 抗体衍生物 |
FI125829B (fi) | 2011-03-07 | 2016-02-29 | Aalto Korkeakoulusã Ã Tiã | Double click-teknologia |
CN103764665A (zh) | 2011-06-28 | 2014-04-30 | 怀特黑德生物医学研究所 | 使用分选酶安装用于蛋白质连接的点击化学柄 |
AU2013245645A1 (en) * | 2012-04-13 | 2014-11-13 | Whitehead Institute For Biomedical Research | Sortase- modified VHH domains and uses thereof |
US20160326266A1 (en) * | 2015-05-10 | 2016-11-10 | Sorrento Therapeutics, Inc. | Chemically-Locked Bispecific Antibodies |
US20180194859A1 (en) * | 2017-01-12 | 2018-07-12 | Sorrento Therapeutics, Inc. | Linked Dual Antibodies Conjugated at a Hinge Region |
-
2015
- 2015-05-10 US US15/310,214 patent/US10435479B2/en active Active
- 2015-05-10 WO PCT/US2015/030054 patent/WO2015175357A1/en active Application Filing
- 2015-05-10 CA CA2948810A patent/CA2948810A1/en active Pending
- 2015-05-10 CN CN201580033933.3A patent/CN106661602B/zh active Active
- 2015-05-10 EP EP15792450.7A patent/EP3143154B1/en active Active
- 2015-05-10 AU AU2015259533A patent/AU2015259533B2/en active Active
- 2015-05-10 JP JP2016567196A patent/JP6687247B2/ja active Active
- 2015-05-10 KR KR1020167034621A patent/KR102460736B1/ko active IP Right Grant
- 2015-05-11 AR ARP150101429A patent/AR100367A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN106661602B (zh) | 2021-03-30 |
EP3143154B1 (en) | 2020-01-29 |
WO2015175357A1 (en) | 2015-11-19 |
WO2015175357A9 (en) | 2016-04-07 |
JP6687247B2 (ja) | 2020-04-22 |
AU2015259533A1 (en) | 2017-01-05 |
CA2948810A1 (en) | 2015-11-19 |
EP3143154A1 (en) | 2017-03-22 |
EP3143154A4 (en) | 2017-11-22 |
KR102460736B1 (ko) | 2022-10-31 |
KR20170002622A (ko) | 2017-01-06 |
JP2017518975A (ja) | 2017-07-13 |
US20170260291A1 (en) | 2017-09-14 |
CN106661602A (zh) | 2017-05-10 |
AU2015259533B2 (en) | 2019-11-28 |
US10435479B2 (en) | 2019-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR100367A1 (es) | Anticuerpos biespecíficos químicamente bloqueados | |
ECSP17081420A (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales | |
ECSP17040521A (es) | Anticuerpos heterodiméricos que se unen a CD3 y a antígenos tumorales | |
CL2017000545A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
MX2018015592A (es) | Anticuerpos inhibidores de puntos de control biespecificos. | |
CO2018011195A2 (es) | Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
CR20220186A (es) | ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225) | |
CR20150482A (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
CL2016002460A1 (es) | Anticuerpos biespecíficos que se unen a cd38 y cd3 | |
AU2016219350A8 (en) | Humanized anti-MUC1* antibodies | |
EA202092435A2 (ru) | Моноклональные антитела против bcma | |
CU24427B1 (es) | Moléculas de anticuerpo que se unen a tim-3 | |
CU24533B1 (es) | Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos | |
BR112017004614A2 (pt) | terapias de combinação com anticorpos anti-cd38 | |
UY36889A (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
BR112017006468A2 (pt) | anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer | |
PH12016500940A1 (en) | HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE | |
CL2017002596A1 (es) | Neutralización del virus chikungunya mediada por anticuerpos | |
CL2019001352A1 (es) | Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo. | |
NZ631098A (en) | Anti-hepcidin antibodies and uses thereof | |
CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
CO2017010631A2 (es) | Método para purificación de proteína | |
CO2017004753A2 (es) | Anticuerpos que se unen a ccr6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |